PuSH - Publikationsserver des Helmholtz Zentrums München

Zeitschriften-Browsing

44 Datensätze gefunden.
Zum Exportieren der Ergebnisse bitte einloggen.
Alle Publikationen dieser Seite in den Korb legen
21.
Arnold, M.* & Quante, A.S.: Personalized mammography screening and screening adherence - a simulation of cost-effectiveness. Value Health 19, A738-A738 (2016)
22.
Danner, M.* et al.: Economic modeling of risk-adapted screen-and-treat strategies in women at high-risk for breast or ovarian cancer. Value Health 19, A737-A738 (2016)
23.
Hoogendoorn, M.* et al.: Patient heterogeneity in health economic decision models for Chronic Obstructive Pulmonary Disease: Are current models suitable to evaluate personalized medicine?. Value Health 19, 800-810 (2016)
25.
Leidl, R. & Reitmeir, P.: Analyzing a German index for the EQ-5D-5L based on experienced health. Value Health 19, A386-A386 (2016)
26.
Szentes, B.L. et al.: Current practice of drug treatment in children with ILD: First insights from the child-EU registry. Value Health 19, A558-A558 (2016)
27.
Walter, J. et al.: Manual compression versus vascular closing device for closing access puncture site in femoral left-heart catheterization and percutaneous coronary interventions: A retrospective cross-sectional comparison of costs and effects in inpatient care. Value Health 20, 769-776 (2016)
28.
Hoogendoorn, M.* et al.: Patient heterogeneity in cost-effectiveness models for Chronic Obstructive Pulmonary Disease (COPD): Are current models suitable to evaluate personalized medicine. Value Health 18:A694 (2015)
29.
Laxy, M. et al.: The burden of diabetes mellitus in patients with coronary heart disease: A methodological approach to assess quality-adjusted life-years based on individual-level longitudinal survey data. Value Health 18, 969-976 (2015)
30.
Brandes, A. et al.: Cost-effectiveness of radical prostatectomy, radiation therapy and active surveillance for the treatment of localized prostate cancer - a claims data analysis. Value Health 17, A636-A637 (2014)
31.
Butzke, B. et al.: Cost-effectiveness analysis of ugt1a1 genotyping before colorectal cancer treatment with irinotecan. Value Health 17, A643 (2014)
32.
Hoogendoorn, M.* et al.: Cost-effectiveness models for chronic obstructive pulmonary disease: Cross-model comparison of hypothetical treatment scenarios. Value Health 17, 525-536 (2014)
33.
Hoogendoorn, M.* et al.: Cost-effectiveness models for Chronic Obstructive Pulmonary Disease (COPD): Cross-model comparison of hypothetical treatment scenarios. Value Health 17, A557-A558 (2014)
34.
Laxy, M. et al.: The intermediate burden of diabetes mellitus in patients with cardiovascular disease (CVD): A quality adjusted life year (QALY) - analysis based on primary longitudinal data. Value Health 17, A494 (2014)
35.
Little, M.H.R. ; Reitmeir, P. ; Peters, A. & Leidl, R.: The impact of differences between patient and general population EQ-5D-3L values on the mean tariff scores of different patient groups. Value Health 17, 364-371 (2014)
36.
Rochau, U.* et al.: Prioritization of future outcomes research studies in chronic myeloid leukemia: Value of information analysis. Value Health 17, A639 (2014)
37.
Leidl, R. ; Reitmeir, P. ; König, H.-H.* & Stark, R.G.: The performance of a value set for the EQ-5D based on experienced health states in patients with inflammatory bowel disease. Value Health 15, 151-157 (2012)
38.
Menn, P. et al.: Dementia care in the general practice setting: A cluster randomized trial on the effectiveness and cost impact of three management strategies. Value Health 15, 851-859 (2012)
39.
Rottenkolber, D. ; Hasford, J.* & Stausberg, J.*: Costs of adverse drug events in German hospitals - a microcosting study. Value Health 15, 868-875 (2012)
40.
Hunger, M. ; Baumert, J.J. & Holle, R.: Analysis of SF-6D index data: Is beta regression appropriate? Value Health 14, 759-767 (2011)